Why the study?
Although cardiac biomarkers are pivotal to clinical practice, much remains to be discovered to benefit cardiology patients.
Key points are not available for this paper at this time.
Design
Review
Framework for biomarker evaluation in ACS and HF; leaves open prospective validation before clinical use.
Cardiac biomarkers have become pivotal to the clinical practice of cardiology, but there remains much to discover that could benefit cardiology patients. We review the discovery of key protein biomarkers in the fields of acute coronary syndrome, heart failure, and atherosclerosis, giving an overview of the populations they were studied in and the statistics that were used to validate them. We review statistical approaches that are currently in use to assess new biomarkers and overview a framework for biomarker discovery and evaluation that could be incorporated into clinical trials to evaluate cardiovascular outcomes in the future.
No takes yet. Share an insight, caveat, or question.
Kott et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: